Roy Morello, Ph.D. (Physiology and Biophysics and Genetics)
Roy Morello, Ph.D. (Physiology and Biophysics and Genetics) Web profile: In my laboratory we study the function of novel genes, in particular those involved ...

By: UAMSHealth

Read this article:
Roy Morello, Ph.D. (Physiology and Biophysics and Genetics) - Video

Recommendation and review posted by Bethany Smith

Bharat Book Pressents : Gene Therapy Technologies, Markets and Companies
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/gene-therapy-technologies-markets-and-companies.html Benefit...

By: Deepa Kamath

Read more:
Bharat Book Pressents : Gene Therapy Technologies, Markets and Companies - Video

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2v6lkd/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 287 of these are profiled in part II of the report along with tabulation of 273 alliances. Of these companies, 158 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 12 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

See more here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles

Recommendation and review posted by simmons

Olympic officials and scientific experts will meet in China next month to review the progress in developing a test for gene doping, the potential future of cheating in sports.

IOC medical commission chairman Arne Ljungqvist said researchers have made significant advances in devising a test, leaving officials hopeful a method can be approved soon for use at the Olympics and other events.

"Quite some progress has been made in terms of outlining the scientific basis for analysis of gene doping," Ljungqvist told The Associated Press. "We are moving. It's promising."

Up to 40 experts from around the world will meet in Beijing on June 5-6 to discuss recent findings and how to move forward in combatting the threat of athletes manipulating their genes to boost sports performance.

The meeting is being organized by the World Anti-Doping Agency in conjunction with China's national anti-doping agency. It will be the Olympic movement's fourth symposium on gene doping, following previous conferences in Cold Spring Harbor, New York, in 2002; Stockholm in 2005; and St. Petersburg, Russia, in 2008.

"There have been scientific studies which are quite promising," said Ljungqvist, also a WADA vice president. "We feel it's time to review this within the context of a small symposium of specialists."

Gene doping, which is prohibited by the IOC and WADA, involves transferring genes directly into human cells to blend into an athlete's own DNA to enhance muscle growth and increase strength or endurance. It is an illegal offshoot of gene therapy, which typically alters a person's DNA to fight diseases like muscular dystrophy and cystic fibrosis.

"We want to continue the momentum that we've got so we can get to a scenario where the detection methods can be approved," WADA director general David Howman told the AP. "It's close."

In 2010, two groups of scientists - one in Germany and a US-French research team - said they developed gene doping tests in what WADA described at the time as a major breakthrough. One was a blood test that would detect doping as far back as 56 days, while the other was for detecting genetic doping in muscles.

However, the tests have not been validated and hopes they could be used at the 2012 London Olympics were not realised.

Originally posted here:
IOC set to combat gene doping with new test

Recommendation and review posted by Bethany Smith

LONDON (AP) -- Olympic officials and scientific experts will meet in China next month to review the progress in developing a test for gene doping, the potential future of cheating in sports.

IOC medical commission chairman Arne Ljungqvist said researchers have made significant advances in devising a test, leaving officials hopeful a method can be approved soon for use at the Olympics and other events.

''Quite some progress has been made in terms of outlining the scientific basis for analysis of gene doping,'' Ljungqvist told The Associated Press. ''We are moving. It's promising.''

Up to 40 experts from around the world will meet in Beijing on June 5-6 to discuss recent findings and how to move forward in combatting the threat of athletes manipulating their genes to boost sports performance.

The meeting is being organized by the World Anti-Doping Agency in conjunction with China's national anti-doping agency. It will be the Olympic movement's fourth symposium on gene doping, following previous conferences in Cold Spring Harbor, New York, in 2002; Stockholm in 2005; and St. Petersburg, Russia, in 2008.

''There have been scientific studies which are quite promising,'' said Ljungqvist, also a WADA vice president. ''We feel it's time to review this within the context of a small symposium of specialists.''

Gene doping, which is prohibited by the IOC and WADA, involves transferring genes directly into human cells to blend into an athlete's own DNA to enhance muscle growth and increase strength or endurance. It is an illegal offshoot of gene therapy, which typically alters a person's DNA to fight diseases like muscular dystrophy and cystic fibrosis.

''We want to continue the momentum that we've got so we can get to a scenario where the detection methods can be approved,'' WADA director general David Howman told the AP. ''It's close.''

In 2010, two groups of scientists - one in Germany and a U.S.-French research team - said they developed gene doping tests in what WADA described at the time as a major breakthrough. One was a blood test that would detect doping as far back as 56 days, while the other was for detecting genetic doping in muscles.

However, the tests have not been validated and hopes they could be used at the 2012 London Olympics were not realized.

Go here to read the rest:
WADA to hold meeting in China on gene doping

Recommendation and review posted by Bethany Smith

May 3, 2013

Brett Smith for redOrbit.com Your Universe Online

When geneticists at the University of Minnesota began work on what they thought was a regulatory gene, they probably had no idea their work would redefine the tiny snippet of genetic material as a key player in stem cell differentiation.

According to the teams report in the journal Cell Stem Cell, the gene Mesp1 is responsible for differentiation of heart, blood and muscle cells from stem cells.

Previous research indicated that this gene was the master regulator for development of the heart, and that its activity prevented the differentiation of other cell types, said co-authorMichael Kyba, an associate professor in the University of Minnesota Medical Schools Department of Pediatrics.

Our work reveals that this gene acts differently, and that it plays a role in the development of blood and skeletal muscle as well, Kyba said.The outcome depends on the chemical signals that cells expressing this factor sense in their environment.

The researchers chose Mesp1 because it was thought to be an important regulator of cardiac differentiation by blocking the delineation of stem cells into other types.

In the study, the researchers examined the activity of Mesp1 to see what it does at different points in the course of a stem cells development and found the gene can affect much more than previously believed.

Using pulse inductions of gene expression after stem cell differentiation, the team found that instead of promoting cardiac cells, the gene causes the development of precursors of different cell types.The effects of the gene could also be seen by fine-tuning the cells culture environment.

This is totally out of the blue, but our discovery brings some conflicting findings about Mesp1 together, said co-author Sunny Chan, a postdoctoral researcher at the University. Some previous studies reported Mesp1 could not make heart cells in certain contexts. We now know why.

Here is the original post:
Mesp1 Gene Links Heart, Blood And Skeletal Muscle

Recommendation and review posted by Bethany Smith

WRT 205 - Evolution of Genetic Engineering
New Project 1.

By: Amber C

Read more:
WRT 205 - Evolution of Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

Mini Seminar (5.c)-Genetic Engineering

By: kobrienSPS

Here is the original post:
Mini Seminar (5.c)-Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

Biotechnology - Cloning Genetic Engineering
Video notes on cloning genetic engineering.

By: Vanita Vance

Read the original here:
Biotechnology - Cloning

Recommendation and review posted by Bethany Smith

Public release date: 3-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, May 2, 2013Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer. A novel, high-throughput screening method used to identify agents that can block one chemical modifier that plays a key role in some forms of cancer is described in ASSAY and Drug Development Technologies, a peer-reviewed journal published from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available on the ASSAY and Drug Development Technologies website (http://www.liebertpub.com/adt).

Jeffrey Simard, Matthew Plant, Renee Emkey, and Violeta Yu, Amgen, Inc. (Cambridge, MA) present an optimized, robust assay for screening large numbers of chemical compounds against EZH2 methyltransferase. This enzyme is part of a multi-protein complex which can alter the methylation state of chromosomal proteins. Increased EZH2 methyltransferase activity has been associated with reduced expression of tumor repressor genes.

In the article "Development and Implementation of a High-Throughput AlphaLISA Assay for Identifying Inhibitors of EZH2 Methyltransferase" (http://online.liebertpub.com/doi/full/10.1089/adt.2012.481) the authors describe the use of AlphaLisa technology to detect methylation by EZH2 and emphasize that this approach should accelerate the identification of small molecule inhibitors for use as research tools and for development as novel anti-cancer therapeutics.

###

About the Journal

Assay and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year in print and online. It provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a complementary sample issue may be viewed on the ASSAY and Drug Development Technologies website ((http://www.liebertpub.com/adt).

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including OMICS: A Journal of Integrative Biology and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).

Original post:
Identifying inhibitors of human proteins that promote tumor formation

Recommendation and review posted by Bethany Smith

Public release date: 3-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 1, 2013Congestive heart failure affects more than 5.3 million Americans, is increasing in prevalence, and is ultimately fatal, but the duration and quality of life leading up to death can be unpredictable and vary greatly. Patients and caregivers could better plan for this difficult time if they knew what to expect. Five of the most common scenarios for the last 12 months of life in end-stage heart failure are clearly described in the article "Trajectory of Illness for Patients with Congestive Heart Failure," published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Journal of Palliative Medicine is the Official Journal of the Center to Advance Palliative Care (CAPC). The article is available on the Journal of Palliative Medicine website (http://www.liebertpub.com/jpm).

Authors R. Kheirbek, et al. from Washington DC Veterans Affairs Medical Center and George Washington University School of Medicine, and Bay Pines Veteran Administration Healthcare System and University of South Florida Morsani College of Medicine, modeled the path to death over the preceding 12 months of 744 patients with progressive congestive heart failure. They found that about 20% of patients had an unexpected death, whereas the remaining had a gradual progression toward death.

From these models the authors identified five different trajectories, in an effort to help bring some degree of predictability to the last 12 months of life for these patients, and help them gain some control over their illness. For example, the authors concluded that it may be possible to use progression towards death over three consecutive months as a predictor of need for Hospice consults.

"Death from heart failure is the leading cause of death in the United States," says Charles F. von Gunten, MD, PhD, Editor-in-Chief of Journal of Palliative Medicine and Clinical Professor of Medicine, University of California, San Diego. "It is high time that, like death from cancer, we plan for the future rather than being surprised when it happens."

###

About the Journal

Journal of Palliative Medicine (http://www.liebertpub.com/jpm), published monthly in print and online, is an interdisciplinary journal that reports on the clinical, educational, legal, and ethical aspects of care for seriously ill and dying patients. The Journal includes coverage of the latest developments in drug and non-drug treatments for patients with life-threatening diseases including cancer, AIDS, cardiac disease, pulmonary, neurological, and respiratory conditions, and other diseases. The Journal reports on the development of palliative care programs around the United States and the world and on innovations in palliative care education.

About the Publisher

See the original post:
Predicting the path to death and helping patients cope with end-stage heart failure

Recommendation and review posted by Bethany Smith

May 3, 2013

redOrbit Staff & Wire Reports Your Universe Online

Researchers have discovered a link between nearsightedness and mutations in a gene partially responsible for the regulation of copper and oxygen levels in eye tissues, according to a paper published in Thursdays edition of the American Journal of Human Genetics.

Nearsightedness, which is also known as myopia, is a condition which results when a persons eye is too long or there is too much curvature in their cornea, which keeps light entering the eye from focusing properly.

A more severe form of the condition, which affects up to two percent of people in the US and is particularly common in Asian population, is known as high-grade myopia and can result in an increased risk of other serious eye conditions such as retinal detachment, cataracts and glaucoma.

Previous research has suggested that nearsightedness is caused by a combination of genetics and environmental influences, such as an overabundance of reading. While the condition has been known to be inherited in families, the specific genetic factors involved have remained unclear leading a team of experts from Duke University Medical Center to further explore the issue by studying families suffering from high-grade myopia.

This is the first time a gene mutation for autosomal dominant nonsyndromic high-grade myopia in Caucasians has been discovered, senior author Terri Young, a professor of ophthalmology, pediatrics and medicine at the Duke Eye Center, Duke Center for Human Genetics and the Duke-National University of Singapore Graduate Medical School (Duke-NUS), said in a statement. Our findings reflect the hard work and collaboration of our international research team.

Young and her colleagues performed next-generation deep sequencing on four members of an 11-member American family of European descent. By analyzing DNA extracted from their blood and saliva, Youngs team identified that mutations in the SCO2 gene were common in family members with high-grade myopia, but absent in those that did not suffer from the condition.

They went on to identify four mutations in the SCO2 gene in an additional 140 people with high-grade myopia, and once those mutations were identified, the researchers examined human eye tissue. In doing so, they verified that this particular gene was expressed in areas of the eye linked to being nearsighted. They then performed experiments on mice which provided further evidence that the gene could play a role in the development of myopia.

Our findings, plus information from the literature, suggest that copper deficiency could predispose people to develop myopia, Young explained. While this wasnt directly tested in this study, its possible that our diets which are deficient in a number of minerals and vitamins play a role, and it may be something as easy as taking a supplement with copper that helps thwart the development of myopia.

Here is the original post:
Genetic Mutation's Role In High-Grade Myopia Examined

Recommendation and review posted by Bethany Smith

Flipping a genetic switch in tumour cells can halt the spread of cancer, scientists have shown.

The discovery raises the possibility of stopping deadly disease in its tracks by blocking the gene, thought to be active in all aggressive cancers.

HGMA1 operates like an orchestra conductor, regulating a range of biological processes tumours need to grow and spread around the body.

Its usual role is to drive cell growth during embryonic development. In healthy adult cells, it is turned off, but the gene is reactivated in cancers.

In laboratory tests, scientists found that suppressing HGMA1 in highly aggressive breast cancer caused the tumour cells to look much more normal and healthy. Their growth was greatly slowed and they stopped migrating and invading new territory.

Breast tumours implanted into mice were far less likely to grow and spread when HGMA1 was blocked.

Dr Linda Resar, from Johns Hopkins University School of Medicine in Baltimore, US, said : "This master regulator is normally turned off in adult cells, but it is very active during embryonic development and in all highly aggressive tumors studied to date.

"Our work shows for the first time that switching this gene off in aggressive cancer cells dramatically changes their appearance and behavior."

HGMA1 plays a role in reprogramming ordinary mature cells into stem cells that can transform themselves into any kind of tissue. One of the major hurdles facing stem cell scientists is the risk of generating tumours by triggering out-of-control cell growth.

The new work developed from research investigating the behaviour of HGMA1 in stem cells.

Read more:
Could This Genetic Switch Halt Spread Of Cancer?

Recommendation and review posted by Bethany Smith

PROVO -- Emily Bates used to suffer from migraines. She hasn't had one recently, but still has a passion for helping those who are afflicted with them.

A professor in the department of chemistry and biochemistry at BYU, she and a team were featured in a cover article of Journal of Science Translational Medicine on Wednesday for research that discovered a genetic link to migraines.

She was quick to explain that not everyone who gets migraines is susceptible because of their genes. Nor is discovering the genetic link a cure for those who do.

"It is kind of a hopeful thing," she said. "It is a hope that we get to understand what is going on. It is really a bizarre disorder. It is kind of a first clue what is going on for a migraine, what makes a person more susceptible."

Migraines can affect anyone, she said.

"You can be taking care of your health in every way and go from a very healthy person to being very incapacitated," she said.

That's how Seth Hawkins feels when a migraine strikes.

"It's pretty miserable," he said. "For me, there's headaches and there's migraines. The pain is excruciating. It's hard to focus on anything. My vision will start to blur, then I get intense nausea, then the headache itself. I become extremely sensitive to light. I have to go into a really dark room. It should be a cool room as well. Heat makes the nausea even worse. I was also sensitive to sound as well.

"It's one of those that you can take stuff, sometimes it helps, sometimes it doesn't. I get them, depending on how stressed I am, an average of two or three times a month. I used to be a schoolteacher and I got them a whole lot more. For me, the biggest help has been understanding what my triggers are and making sure I don't engage those. My two biggest are not getting enough water, and stress. If I can keep my stress level down I usually don't get migraines."

"A lot of times I will get them in the middle of the day," he said. "I will think I can tough it out. It makes it worse. Unless I'm lying down waiting for medication to kick in, it doesn't help. Sometimes it lasts three, four or five hours on end. If I take the medication, from the time I take it to the time the migraine actually starts to wear off, is usually one or two hours.

Go here to see the original:
BYU professor helps discover genetic link to migraines

Recommendation and review posted by Bethany Smith

Some of the most devastating forms of cancer have genetic similarities even though they strike different body parts, according to new studies out Thursday.

The new research -- one study focused on a form of leukemia, in the New England Journal of Medicine, and a second on endometrial cancer, in Nature -- could offer a pathway to new, more effective treatments.

The new findings challenge the previous approach of classifying tumors based on the body part where they are first observed, and add fuel to the growing trend of differentiating tumors based on their genetic profile.

The research came as part of a vast program undertaken by the National Institutes of Health called the "Cancer Genome Atlas Project," which aims to decode the genetic pattern of 10,000 tumors from 20 different cancers.

Thanks to that analysis, scientists had already found genetic relationships between certain forms of breast, lung, and colon cancers.

For example, one type of breast cancer presents genetic mutations very similar to the ones found in ovarian cancer, and colon cancers often have mutations found in breast cancer.

The researchers said around half of all lung cancers could respond to treatments used against other kinds of tumors.

The latest study found the most aggressive form of endometrial cancer, which affects the uterine lining, is similar to more grave forms of breast and ovarian cancer.

"The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma, or HGSOC, are quite similar," wrote the authors of the study published in Nature, which analyzed more than 370 tumors.

Likewise, "HGSOC shares many similar molecular features with basal-like breast carcinoma," added the team, which was directed by Douglas Levine of Memorial Sloan Kettering Cancer Center, in New York.

Read the rest here:
US studies find genetic links in aggressive cancers

Recommendation and review posted by Bethany Smith

SOME of the most devastating forms of cancer have genetic similarities even though they strike different body parts.

The new research - one study focused on a form of leukaemia, in the New England Journal of Medicine, and a second on endometrial cancer, in Nature - could provide a pathway to new, more effective treatments.

The findings, released on Thursday, challenge the previous approach of classifying tumours based on the body part where they are first observed, and add to the growing trend of differentiating tumours based on their genetic profile.

The research is part of a vast program by the National Institutes of Health known as the Cancer Genome Atlas Project, which aims to decode the genetic pattern of 10,000 tumours from 20 different cancers.

Scientists have already found genetic relationships between certain forms of breast, lung, and colon cancers.

For example, one type of breast cancer presents genetic mutations very similar to the ones found in ovarian cancer, and colon cancers often have mutations found in breast cancer.

The researchers said about half of all lung cancers could respond to treatments used against other kinds of tumours.

The latest study found the most aggressive form of endometrial cancer, which affects the uterine lining, is similar to more grave forms of breast and ovarian cancer.

"The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma, or HGSOC, are quite similar," wrote the authors of the study published in Nature, which analysed more than 370 tumours.

Likewise, "HGSOC shares many similar molecular features with basal-like breast carcinoma," added the team, which was directed by Douglas Levine of Memorial Sloan Kettering Cancer Center, in New York.

Follow this link:
Genetic links in aggressive cancer

Recommendation and review posted by Bethany Smith

Young Engineer of the Year builds his own genetics lab
Young Engineer of the Year builds his own genetics lab Subscribe to the Guardian HERE: http://bitly.com/UvkFpD Fred Turner, Young Engineer of the Year 2013, ...

By: TheGuardian

See original here:
Young Engineer of the Year builds his own genetics lab - Video

Recommendation and review posted by Bethany Smith

Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis
A presentation by Stephanie Cherqui, PhD, University of California, San Diego at the 2013 Day of Hope Cystinosis Research Foundation Family Conference, Balbo...

By: Natalieswish

Here is the original post:
Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis - Video

Recommendation and review posted by Bethany Smith

Hope - It #39;s In Our Genes: Dr. Barry Byrne at TEDxUF 2013
Over the past 20 years, a revolution in medicine has been developing. Since the discovery of DNA, scientists have be a decoding the origins of human disease ...

By: TEDxTalks

Here is the original post:
Hope - It's In Our Genes: Dr. Barry Byrne at TEDxUF 2013 - Video

Recommendation and review posted by Bethany Smith

The State of Personalized Medicine for Breast Cancer
Dr. Alana Welm of the Huntsman Cancer Institute, Utah, although a young investigator, has made a significant impact on the study-particularly the metastasis-...

By: Lynn Marquis

Read the original post:
The State of Personalized Medicine for Breast Cancer - Video

Recommendation and review posted by sam

Denis Nogueira - Reabilitao/Musculao (Leso Medular C5) - (recovery - spinal cord injury)
Treino na academia Kcond #39;s Fitness (Marcos Navarro) e preparador fsico Beto. Sou lesado medular desde 02/11/2009, e tenho sempre evoludo. "These are some e...

By: DenisNogueiraOficial

See the rest here:
Denis Nogueira - Reabilitação/Musculação (Lesão Medular C5) - (recovery - spinal cord injury) - Video

Recommendation and review posted by sam

Stem Cell Treatments for Spinal Cord Injury: Theo K. - Stem Cell Institute Panama
Theo Kostoulas is a T-6 complete spinal cord injury patient. He received a course of 16 stem cell therapy injections using umbilical cord-derived stem cells ...

By: cellmedicine

Read the rest here:
Stem Cell Treatments for Spinal Cord Injury: Theo K. - Stem Cell Institute Panama - Video

Recommendation and review posted by sam

Poor funding for spinal cord injury independent living
in the 3 1/2 years I have been fighting to live at home independently I have learned that in the United States is nearly impossible for someone with a severe...

By: Jesse Collens

View post:
Poor funding for spinal cord injury independent living - Video

Recommendation and review posted by sam

67 WALL STREET, New York - May 1, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation

Companies include: Celgene Corporation (CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX), Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc. (PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc. (IMGN) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors:

TWST: What have been some of the biggest successes and which have been the companies with the biggest successes?

Mr. Peaker: In terms of successes in the oncology space, on the larger-cap side we've had some positive news from Celgene (CELG) for this drug called Pomalyst in myeloma. It's a relatively limited market in our view at this point, but still a novel compound for a high-profile indication.

Recently, Amgen (AMGN) reported very interesting topline results from a melanoma drug, which is also very exciting. We don't know the details, but at least the top line sounds encouraging. My top pick has been and remains at this time, Celldex (CLDX). I think that their targeted antibody-drug conjugate drug is highly innovative and showed very encouraging data.

In cell therapy, I follow several cell therapy companies. Recently there was some negative development for Aastrom (ASTM), which was not surprising. Basically, what it comes down to, and it's something that's always been our thesis, is that while cell therapy may seem attractive because it tends to be very safe and not really have the side effects of traditional oncology drugs, it also has to be relatively easy for the patient and have a pretty broad-based indication. So the reason Aastrom discontinued clinical development wasn't because of failure of outcome for its therapy. It's simply they couldn't get the patient into the study.

It's always been our concern about their particular situation because the actual harvesting of the cell is pretty inconvenient for the patient, and they have such a narrow recruiting criteria that when you put those two together, they couldn't even run a study realistically getting those patients. So cell therapy remains a very interesting area, but I think that there's still a lot...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

More:
A Cautious Outlook on the Cell Therapy Space: Expert Analyst Boris Peaker Interviews with The Wall Street Transcript ...

Recommendation and review posted by Bethany Smith

67 WALL STREET, New York - May 1, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation

Companies include: Celgene Corporation (CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX), Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc. (PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc. (IMGN) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors:

TWST: What have been some of the biggest successes and which have been the companies with the biggest successes?

Mr. Peaker: In terms of successes in the oncology space, on the larger-cap side we've had some positive news from Celgene (CELG) for this drug called Pomalyst in myeloma. It's a relatively limited market in our view at this point, but still a novel compound for a high-profile indication.

Recently, Amgen (AMGN) reported very interesting topline results from a melanoma drug, which is also very exciting. We don't know the details, but at least the top line sounds encouraging. My top pick has been and remains at this time, Celldex (CLDX). I think that their targeted antibody-drug conjugate drug is highly innovative and showed very encouraging data.

In cell therapy, I follow several cell therapy companies. Recently there was some negative development for Aastrom (ASTM), which was not surprising. Basically, what it comes down to, and it's something that's always been our thesis, is that while cell therapy may seem attractive because it tends to be very safe and not really have the side effects of traditional oncology drugs, it also has to be relatively easy for the patient and have a pretty broad-based indication. So the reason Aastrom discontinued clinical development wasn't because of failure of outcome for its therapy. It's simply they couldn't get the patient into the study.

It's always been our concern about their particular situation because the actual harvesting of the cell is pretty inconvenient for the patient, and they have such a narrow recruiting criteria that when you put those two together, they couldn't even run a study realistically getting those patients. So cell therapy remains a very interesting area, but I think that there's still a lot...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

See the rest here:
Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs: A Wall Street Transcript Interview ...

Recommendation and review posted by Bethany Smith